SBFM vs TPVG vs CRVS vs HRZN

For growth investors, Sunshine Biopharma, Inc.

(SBFM) is the stronger pick with 44. 7% revenue growth year-over-year, versus 17. 9% for Horizon Technology Finance Corporation (HRZN). Horizon Technology Finance Corporation (HRZN) offers the better valuation at 4. 3x trailing P/E (6. 0x forward), making it the more compelling value choice. Analysts rate Corvus Pharmaceuticals, Inc. (CRVS) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Horizon Technology Finance Corporation (HRZN) is the cheapest at 4.

3x versus TriplePoint Venture Growth BDC Corp. at 4. 7x. On forward P/E, Horizon Technology Finance Corporation is actually cheaper at 6. 0x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Horizon Technology Finance Corporation wins at 0. 25x versus TriplePoint Venture Growth BDC Corp. 's 6. 14x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Corvus Pharmaceuticals, Inc.

(CRVS) delivered a total return of +507. 4%, compared to -100. 0% for Sunshine Biopharma, Inc. (SBFM). Over 10 years, the gap is even starker: TPVG returned +91. 2% versus SBFM's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Horizon Technology Finance Corporation (HRZN) is the lower-risk stock at 0.

77β versus Corvus Pharmaceuticals, Inc. 's 1. 57β — meaning CRVS is approximately 105% more volatile than HRZN relative to the S&P 500. On balance sheet safety, Corvus Pharmaceuticals, Inc. (CRVS) carries a lower debt/equity ratio of 2% versus 149% for Horizon Technology Finance Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Sunshine Biopharma, Inc.

(SBFM) is pulling ahead at 44. 7% versus 17. 9% for Horizon Technology Finance Corporation (HRZN). On earnings-per-share growth, the picture is similar: Horizon Technology Finance Corporation grew EPS 756. 3% year-over-year, compared to 48. 0% for Corvus Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

TriplePoint Venture Growth BDC Corp.

(TPVG) is the more profitable company, earning 50. 6% net margin versus -14. 7% for Sunshine Biopharma, Inc. — meaning it keeps 50. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TPVG leads at 77. 9% versus -16. 7% for SBFM. At the gross margin level — before operating expenses — TPVG leads at 83. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Horizon Technology Finance Corporation (HRZN) is the more undervalued stock at a PEG of 0. 25x versus TriplePoint Venture Growth BDC Corp. 's 6. 14x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Horizon Technology Finance Corporation (HRZN) trades at 6. 0x forward P/E versus 6. 2x for TriplePoint Venture Growth BDC Corp. — 0. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CRVS: 113. 3% to $33. 17.

In this comparison, HRZN (27.

6% yield), TPVG (17. 8% yield) pay a dividend. SBFM, CRVS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, TriplePoint Venture Growth BDC Corp.

(TPVG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 77), 17. 8% yield). Corvus Pharmaceuticals, Inc. (CRVS) carries a higher beta of 1. 57 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TPVG: +91. 2%, CRVS: +24. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SBFM (Healthcare) and TPVG (Financial Services) and CRVS (Healthcare) and HRZN (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SBFM is a small-cap high-growth stock; TPVG is a small-cap high-growth stock; CRVS is a small-cap quality compounder stock; HRZN is a small-cap high-growth stock. TPVG, HRZN pay a dividend while SBFM, CRVS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.